Suven Life Sciences (Suven) has been granted one product patent from Canada, one product patent from Europe and one product patent from Hong Kong corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030, 2032 and 2032 respectively.
The granted claims of the patents are from the mechanism of action include the class of selective 5-HT4 compounds and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, Suven has a total of twenty four granted patents from Canada, twenty two granted patents from Europe and twenty one granted patents from Hong Kong. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
